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ARTICLE
Creatine uptake regulates CD8 T cell antitumor
immunity
Stefano Di Biase1*, Xiaoya Ma1*, Xi Wang1, Jiaji Yu1, Yu-Chen Wang1, Drake J. Smith1, Yang Zhou1, Zhe Li1, Yu Jeong Kim1, Nicole Clarke1, Angela To1,
and Lili Yang1,2,3,4
T cells demand massive energy to combat cancer; however, the metabolic regulators controlling antitumor T cell immunity
have just begun to be unveiled. When studying nutrient usage of tumor-infiltrating immune cells in mice, we detected a sharp
increase of the expression of a CrT (Slc6a8) gene, which encodes a surface transporter controlling the uptake of creatine into
a cell. Using CrT knockout mice, we showed that creatine uptake deficiency severely impaired antitumor T cell immunity.
Supplementing creatine to WT mice significantly suppressed tumor growth in multiple mouse tumor models, and the
combination of creatine supplementation with a PD-1/PD-L1 blockade treatment showed synergistic tumor suppression
efficacy. We further demonstrated that creatine acts as a “molecular battery” conserving bioenergy to power T cell activities.
Therefore, our results have identified creatine as an important metabolic regulator controlling antitumor T cell immunity,
underscoring the potential of creatine supplementation to improve T cell–based cancer immunotherapies.
Introduction
T cells play a central role in mediating and orchestrating im-
mune responses against cancer; therefore, they are attractive
therapeutic targets for treating cancer (Couzin-Frankel, 2013;
Page et al., 2014; Ribas, 2015; Rosenberg and Restifo, 2015;
Baumeister et al., 2016; Lim and June, 2017). The maintenance
and activation of T cells are energy-demanding activities, re-
quiring the use of bioenergy in the form of ATP (Fox et al.,
2005). Distinct metabolic programs are used by T cells to gen-
erate ATP to support their diverse homeostatic and effector
functions (Fox et al., 2005; O’Neill et al., 2016; Kidani and
Bensinger, 2017; Zeng and Chi, 2017). In the tumor microenvi-
ronment, T cells face the special challenge of competing with
fast-growing tumor cells for metabolic fuel such as glucose,
amino acids, and lipids, which can be limiting (McCarthy et al.,
2013). Therefore, an efficient and economical bioenergy me-
tabolism is needed for tumor-infiltrating T cells to mount and
sustain effective anticancer responses (Siska and Rathmell,
2015). However, the study of metabolic regulators controlling
antitumor T cell immunity has just begun (Chang and Pearce,
2016; Ho and Kaech, 2017; Kishton et al., 2017; Patel and Powell,
2017). Herewe show that creatine is a critical molecule buffering
ATP levels in cancer-targeting CD8 T cells through maintain-
ing a readily available high-energy phosphate reservoir (Wyss
and Kaddurah-Daouk, 2000). We found that tumor-infiltrating
immune cells (TIIs) up-regulated their expression of the creatine
transporter gene (Slc6a8 or CrT), which encodes a surface
transporter controlling the uptake of creatine into a cell (Wyss
and Kaddurah-Daouk, 2000). Creatine uptake deficiency se-
verely impaired CD8 T cell responses to tumor challenge in vivo
and to antigen stimulation in vitro, while supplementation of
creatine through either direct administration or dietary sup-
plement significantly suppressed tumor growth in multiple
mouse tumor models. Notably, the combination of creatine
supplementation with a checkpoint inhibitor blockade treat-
ment, such as the PD-1/PD-L1 blockade, showed a synergistic
tumor suppression effect, suggesting that creatine supplemen-
tation can be a valuable component for combination cancer
immunotherapies. Therefore, our results have identified crea-
tine as an important “molecular battery” that conserves bio-
energy to enhance antitumor T cell immunity, underscoring the
potential of creatine supplementation to improve T cell–based
cancer immunotherapies.
Results
Creatine transporter gene (CrT) is up-regulated in TIIs
To identify metabolic regulators controlling tumor-fighting
immune cells, we grew solid B16-OVA melanoma tumors in
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C57BL/6J mice, isolated TIIs, and then studied their gene ex-
pression profile relevant to nutrient usage using quantitative
RT-PCR (qPCR). Immune cells isolated from the spleen of tumor-
bearing or tumor-free mice were included as controls. Inter-
estingly, in addition to the change of genes involved in the
classic glucose/lipid/amino acid metabolic pathways (Fox et al.,
2005), we detected a sharp increase of the expression of a CrT
(Slc6a8) gene in TIIs (Fig. 1 A). CrT is an X-linked gene encoding a
surface transporter (creatine transporter [CrT]) that controls
the uptake of creatine into a cell in an Na+/K+-dependent
manner, where creatine is used to store high-energy phosphates
and to buffer intracellular ATP levels through a CK/PCr/Cr
(creatine kinase/phospho-creatine/creatine) system (Fig. 1 B;
Wyss and Kaddurah-Daouk, 2000).
Creatine is a nitrogenous organic acid that naturally occurs in
vertebrates. It is mainly produced in the liver and kidneys but
predominantly stored in skeletal muscle (Wyss and Kaddurah-
Daouk, 2000). For humans, diet is also amajor source of creatine
(Wyss and Kaddurah-Daouk, 2000). Expression of CrT is im-
portant for cells demanding high energy, such as muscle cells
and brain cells; in humans, CrT deficiency has been associated
with muscle diseases and neurological disorders (Wyss and
Kaddurah-Daouk, 2000). On the other hand, oral creatine
supplements have been broadly used by bodybuilders and ath-
letes to gain muscle mass and to improve performance (Kreider
et al., 2017). However, the function of CrT/creatine outside of
the muscle and brain tissues is largely unknown. Since we found
up-regulated CrT gene expression in TIIs, we asked if the CrT/
creatine system might also regulate the energy metabolism of
tumor-fighting immune cells, in particular CD8 cytotoxic T cells,
which have a massive demand for energy and can benefit from
an energy storage/ATP buffering system (Fig. 1 B).
CrT-KO mice show impeded control of tumor growth
To address this question, we began by studying CrT-KO mice
(Fig. S1 A; Skelton et al., 2011). Despite their smaller body size,
CrT-KO mice contained normal numbers of immune cells, in-
cluding T cells, proportional to their body weight (Fig. S1, B–G).
Before tumor challenge, these T cells displayed a typical naive
phenotype (CD25loCD69loCD62LhiCD44lo; Fig. S1 H). In a B16-
OVAmelanomamodel, tumor growth was accelerated in CrT-KO
mice compared with their CrT-WT littermates (Fig. 1, C and D).
In CrT-KO mice, tumor-infiltrating CD8 T cells expressed higher
levels of PD-1, which has been associated with bioenergy in-
sufficiency and T cell exhaustion, indicating that CrT deficiency
may impact antitumor T cell activities (Fig. 1, E–G; Chang et al.,
Figure 1. CrT-KO mice show impeded control
of tumor growth. (A) Creatine transporter (CrT
or Slc6a8) mRNA expression in spleen (SP) cells
and TIIs in a mouse B16-OVA melanoma model
(n = 3–4) measured by qPCR. Cells were col-
lected on day 14 after tumor challenge.
(B) Diagram showing creatine uptake and
creatine-mediated bioenergy buffering in cells with
high-energy demand. Cr, creatine; PCr, phospho-
creatine; Crn, creatinine; CK, creatine kinase.
(C–G) Study of B16-OVA tumor growth in CrT-
WT or CrT-KO littermate mice. (C) Experimental
design. (D) Tumor growth (n = 3). (E–G) On day
14, tumors were collected from experimental
mice, and TIIs were isolated for further analysis.
(E) FACS plots showing the detection of tumor-
infiltrating CD4 and CD8 T cells (gated as
TCRβ+CD4+ and TCRβ+CD8+ cells, respectively).
(F) FACS plot showing PD-1 expression on
tumor-infiltrating CD8 T cells. (G) Quantification
of F (n = 3). Representative of two (A) and three
(C–G) experiments, respectively. Data are pre-
sented as the mean ± SEM. *, P < 0.05; **, P <
0.01 by one-way ANOVA (A) or Student’s t test
(D and G). See also Fig. S1.
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2015; Wherry and Kurachi, 2015; Bengsch et al., 2016). Of note,
the regularmouse diet (PicoLab Rodent Diet 20) does not contain
creatine; therefore, to mimic the supply of creatine from dietary
resources in humans, we supplied creatine to experimental mice
via i.p. injection (Fig. 1 C). Without i.p. injection of creatine, no
B16-OVA tumor growth difference was observed between CrT-
WT and CrT-KOmice, likely due to the lack of sufficient creatine
supply in these experimental mice to read out the creatine up-
take difference between CrT-WT and CrT-KOmice (Fig. S1, I and J).
Interestingly, study of CrT gene expression in tumor-infiltrating
WT CD8 T cell subsets showed an up-regulation of CrT gene
expression that was more significant in the PD-1hi subset than in
the PD-1lo subset, suggesting a possible feedback loop in PD-1hi
CD8 T cells that compensates for bioenergy insufficiency by in-
creasing creatine uptake (Fig. S1 K). In particular, the PD-1hiTim-
3hiLAG-3hi tumor-infiltrating CD8 T cells, which are considered
to be the most “exhausted,” expressed the highest levels of CrT,
suggesting that these cells may also benefit the most from cre-
atine supplementation treatment (Fig. S1 K; Nguyen and Ohashi,
2015; Wherry and Kurachi, 2015).
Creatine uptake deficiency directly impairs antitumor
T cell immunity
To study the direct regulation of immune cells by CrT, we re-
constituted WT BoyJ mice with bone marrow (BM) cells from
either CrT-WT or CrT-KO donor mice and then challenged re-
cipient mice with B16-OVA tumor cells (Fig. S2 A). CrT defi-
ciency did not impair the reconstitution of an immune system in
the recipient mice (Fig. S2, B and C), but it did impede the ca-
pacity of the reconstituted immune system to control tumor
growth (Fig. S2 D). To further study the direct regulation of
tumor-specific CD8 T cells by CrT, we bred CrT-KO mice with
OT1 transgenic (Tg) mice and generated OT1TgCrT-KO mice pro-
ducing OVA-specific CD8 T cells deficient in CrT (Fig. S2 E). We
isolated OT1CrT-WT and OT1CrT-KO CD8 T cells (Fig. S2 F) and
separately transferred these T cells into BoyJ WT mice bearing
preestablished B16-OVA tumors (Fig. 2 A). Compared with
OT1CrT-WT cells, OT1CrT-KO cells were less effective in controlling
tumor growth (Fig. 2 B). Although OT1CrT-KO cells infiltrated tumors
and showed an antigen-experienced phenotype (CD62LloCD44hi;
Fig. 2, C and D; and Fig. S2 G), these T cells expressed higher levels
of PD-1 (Fig. 2, E and F; and Fig. S2 G) and produced a smaller
amount of effector cytokines, including IL-2 (Fig. 2, G and H) and
IFN-γ (Fig. S2, H and I), compared with OT1CrT-WT cells. Similarly,
mice in these tumor experiments received i.p. injection of crea-
tine to compensate for the lack of creatine supply from mouse
diet (Fig. 1 C, Fig. S2 A, and Fig. 2 A). Collectively, these in vivo
data demonstrate that creatine uptake deficiency directly impairs
antitumor immunity, especially the antitumor efficacy of tumor
antigen–specific CD8 cytotoxic T cells.
Creatine uptake regulates CD8 T cell response to
antigen stimulation
Next, to study how creatine uptake regulates CD8 T cell response
to antigen stimulation, we isolated CD8 T cells from CrT-WT or
CrT-KO littermate mice, followed by stimulating these cells
in vitro with anti-CD3. A standard T cell culture medium was
used,which comprised 10%FBS as the source of creatine (Fig. S3 A).
After stimulation, WT CD8 T cells showed up-regulated ex-
pression of CrT mRNA (Fig. 3 A) and CrT protein (Fig. 3 B), in-
dicating the induction of CrT expression by TCR signaling and
suggesting, in turn, the need for activated CD8 T cells to uptake
more creatine. Compared with their CrT-WT counterparts, CrT-
KO CD8 T cells showed a reduction in almost all aspects of T cell
activation, including cell proliferation (Fig. 3 C), effector cytokine
production (e.g., IL-2 and IFN-γ; Fig. 3, E–G and J–L), surface
activation marker expression (e.g., CD25; Fig. 3, H and I), and
cytotoxic molecule production (e.g., Granzyme B; Fig. 3, M and
N). Cell survival, studied via Annexin V and 7-aminoactinomycin
D (7-AAD) staining, was not affected over a 4-d cell culture period
(Fig. 3 D). Study of OVA-specific OT1CrT-KO CD8 T cells gave
similar results (Fig. S3, B–J), suggesting a general role of CrT in
regulating CD8 T cells of diverse antigen specificities. To verify
whether creatine uptake deficiency directly contributed to the
hyporesponsiveness of the CrT-KO CD8 T cells, we conducted a
rescue experiment. We constructed a MIG-CrT retroviral vector
(Fig. 3 O), used this vector to transduce CrT-KO CD8 T cells, and
finally achieved overexpression of CrT in these cells (Fig. 3, P andQ).
CrT overexpression rescued the activation of CrT-KO CD8 T cells
and improved their production of multiple effector cytokines
(Fig. 3, R and S; and Fig. S3, K and L). Taken together, these data
indicate that CD8 T cells, after antigen stimulation, increase their
capacity to uptake creatine that is critical for them to manifest a
productive effector T cell response.
Creatine uptake modulates CD8 T cell activation by regulating
T cell ATP/energy buffering
It has been well characterized that muscle cells and brain cells
uptake creatine through CrT and then use creatine to buffer
intracellular ATP levels and power cellular activities via a CK/
PCr/Cr system (Wyss and Kaddurah-Daouk, 2000). Therefore,
we investigated whether CD8 T cells might use a similar mo-
lecular mechanism (Fig. 4 A). After TCR stimulation, WT CD8
T cells up-regulated CrT gene expression, enabling the activated
T cells to more effectively uptake creatine (Fig. 4 B). CD8 T cells
expressed high basal levels of Ckb (creatine kinase brain form)
gene, the expression of which was further up-regulated after
TCR stimulation, maximizing the capacity of activated CD8
T cells to use the CK/PCr/Cr ATP buffering system (Fig. 4 C).
De novo synthesized creatinemight be another source to feed
the CK/PCr/Cr system. Consequently, we examined the ex-
pression of genes encoding the two enzymes controlling creatine
biosynthesis, Agat (L-arginine:glycine amidinotransferase) and
Gamt (guanidinoacetate N-methyltransferase). We found that
CD8 T cells expressed low levels of both genes and further down-
regulated the expression of Gamt gene after TCR stimulation
(Fig. 4, D and E). Therefore, activated CD8 T cells may have
limited capacity to synthesize creatine de novo and may,
therefore, heavily rely on importing creatine via CrT from ex-
tracellular sources to feed the CK/PCr/Cr ATP-buffering system.
In agreement with this notion, compared with CrT-WT CD8
T cells, activated CrT-KO CD8 T cells contained undetectable
levels of intracellular creatine (Fig. 4 G) and significantly re-
duced ATP (Fig. 4 F; Wyss and Kaddurah-Daouk, 2000). The
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hypoactivation of CrT-KO CD8 T cells was rescued by supple-
menting ATP in T cell culture, evidenced by increased expres-
sion of T cell surface activation marker CD25 and enhanced
production of effector cytokine IFN-γ (Fig. 4, H–J). Supple-
menting ATP further enhanced the activation of CrT-WT CD8
T cells (Fig. S4, A and B). ATP supplies bioenergy and phosphate
group for TCR signaling events (Patel and Powell, 2017). By
comparing the major TCR signaling pathways in CrT-WT and
CrT-KO CD8 T cells, we found that creatine uptake deficiency
impeded activation of the TCR proximal signaling molecule Zap-
70 (zeta chain of TCR-associated protein kinase 70) and the
downstream transcription factors NFAT and c-Jun (Jun proto-
oncogene, AP-1 transcription factor subunit), which, at least
partially, accounted for the hypoactivation of CrT-KO CD8 T cells
(Fig. 4 K). Creatine supplementation significantly increased Zap-
70 phosphorylation in CrT-WT CD8 T cells but not in CrT-KO
CD8 T cells (Fig. S4 E). The TCR signaling deficiencies in CrT-KO
CD8 T cells were effectively rescued by supplementing ATP to
the T cell culture (Fig. 4 L).
Interestingly, comparedwith the activation of NFAT andAP-1,
the activation of NF-κB, in particular its p65 subunit, was less
sensitive to CrT deficiency–induced ATP shortage, suggesting
that the NF-κB signaling pathway may better resist ATP fluc-
tuation during T cell response (Fig. 4, K and L). AMPK (59 ade-
nosine monophosphate-activated protein kinase) is an enzyme
that detects shifts in the AMP:ATP ratio within a cell. It serves as
a nutrient and energy sensor to maintain cell energy homeo-
stasis and has been indicated to regulate T cell metabolism and
function (Tama´s et al., 2006; Hardie et al., 2012; Rao et al., 2016;
Ma et al., 2017). We therefore examined the possible role of
AMPK in mediating the CrT-KO CD8 T cell hypoactivation
phenotype. In correspondence with the decreased ATP levels in
CrT-KO CD8 T cells, we detected increased activation of AMPK
in these cells compared with that in CrT-WT CD8 T cells (Fig. 4, F
and M). Treating CrT-WT and CrT-KO CD8 T cells with AICAR
(5-aminoimidazole-4-carboxamide 1-β-D-ribofuranoside; an
AMPK activator) markedly activated AMPK in both T cells
(Fig. 4 M), and was associated with a significant reduction of AP-1
transcription factor activation (c-Jun subunit; Fig. 4 M), cell
surface activation marker expression (CD25; Fig. S4 C), and
effector cytokine production (IL-2; Fig. S4 D) in both T cells.
Meanwhile, the activation of Zap-70 and NFAT were not
Figure 2. Creatine uptake deficiency directly impairs antitumor T cell immunity. B16-OVA tumor growth in BoyJ mice was studied. BoyJ mice received
adoptive transfer of OVA-specific OT1 Tg CD8 T cells that were either WT or KO of CrT gene (OT1CrT-WT or OT1CrT-KO cells, respectively). (A) Experimental
design. (B) Tumor growth (n = 9). (C–H) On day 20, tumors were collected from experimental mice, and TIIs were isolated for further analysis. (C) FACS plots
showing the detection of tumor-infiltrating OT1 T cells (gated as CD45.2+CD8+ cells). (D)Quantification of C (n = 9). (E) FACS plots showing PD-1 expression on
tumor-infiltrating OT1 T cells. (F) Quantification of E (n = 9). (G) FACS plots showing intracellular IL-2 production of tumor-infiltrating OT1 T cells. Before
intracellular cytokine staining, TIIs were stimulated with PMA and ionomycin in the presence of GolgiStop for 4 h. (H) Quantification of G (n = 8). Repre-
sentative of two experiments (A–H). Data are presented as the mean ± SEM. ns, not significant; *, P < 0.05 by Student’s t test. See also Fig. S2.
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affected by AICAR treatment (Fig. 4 M). Hence, creatine uptake
modulation of bioenergy homeostasis in CD8 T cells may be
monitored and regulated by AMPK, at least partly through
AMPK regulation of the AP-1 pathway. Collectively, these results
support an intriguing working model in which activated CD8
T cells (1) employ a potent creatine-mediated ATP/energy
buffering system to sustain TCR signaling and power T cell ef-
fector functions, at least partly through ATP/AMPK regulation
of TCR signaling pathways; and (2) rely on importing creatine
via CrT from extracellular sources (Fig. 4 N).
Creatine supplementation for cancer immunotherapy
The “creatine-uptake/energy-buffering” working model (Fig. 4 N)
opens up the possibility of reinvigorating disease-responding
CD8 T cells, in particular tumor-fighting CD8 T cells, through
creatine supplementation. To test this new concept of metabolic
reprogramming and cancer immunotherapy, we supplemented
creatine to experimental C57BL/6J WT mice in the B16-OVA
melanoma model, through either i.p. injection or dietary sup-
plementation (Fig. 5 A). Notably, the dietary supplemental dose
we used (0.4 g/kg body weight) is comparable to the safe loading
dose recommended for athletes (Kreider et al., 2017). Both ad-
ministration routes elevated creatine concentrations in blood to
a similar level (Fig. 5 B) and effectively suppressed tumor
growth to a similar extent (Fig. 5 C). The tumor suppression
effect was associated with a significant reduction of the
“exhaustion-prone” phenotype cells (gated as PD-1hiCD62Llo)
among the tumor-infiltrating CD8 T cells (Fig. 5, D and E). In
agreement with the muscle-enhancement effect of creatine,
we observed an enlargement of skeletal muscle fibers in mice
Figure 3. Creatine uptake regulates CD8 T cell response to antigen stimulation. (A–N) CD8 T cells were purified from CrT-WT or CrT-KO mice and
stimulated in vitro with plate-bound anti-CD3 (5 µg/ml; n = 3–4). The analyses of CrTmRNA expression (A), CrT protein expression (B), cell proliferation (C), cell
survival (D), effector cytokine production (E–G and J–L), activation marker expression (H and I), and cytotoxic molecule production (M and N) are shown, either
over a 4- to 5-d time course (A, C, D, E, and J) or 48 h after anti-CD3 stimulation (F–I and K–N). (O–S) CrT-KO CD8 T cells were stimulated in vitro with anti-CD3
and transduced with a MIG-CrT retrovector (O; n = 3). The analyses of retrovector transduction rate (P), CrT mRNA expression (Q), and IL-2 effector cytokine
production (R and S) 96 h after stimulation are shown. Representative of two (O–S) and three (A–N) experiments, respectively. Data are presented as the
mean ± SEM. ns, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 by Student’s t test. See also Fig. S3.
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receiving creatine supplements (Fig. 5, F and G; Wyss and
Kaddurah-Daouk, 2000; Kreider et al., 2017). On the other
hand, B16-OVA tumors grown in immunodeficient NSG mice
(Fig. 5, H and I) or in C57BL/6J WT mice depleted of T cells via
i.p. injection of an anti-CD3 depletion antibody (Fig. 5, J and K;
and Fig. S5 A) could not be suppressed by creatine supplemen-
tation, confirming that the therapeutic effect of creatine sup-
plementation is mediated by immune cells, in particular T cells.
Figure 4. Creatine uptake modulates CD8 T cell activation by regulating T cell ATP/energy buffering. (A) Schematic of creatine-mediated ATP/energy
buffering. (B–E) CrT-WT CD8 T cells were stimulated with anti-CD3 and analyzed for mRNA expression of creatine transporter (CrT; B), Ckb (C), and two enzymes
controlling the de novo synthesis of creatine, Agat (D) and Gamt (E). n = 3–9. A.U., artificial unit relative to Ube2d2. (F and G) CrT-WT and CrT-KO CD8 T cells were
stimulatedwith anti-CD3 and analyzed for intracellular levels of ATP over time (F) and creatine at 48 h (G). n = 4. (H–J) CrT-KO CD8 T cells were stimulatedwith anti-
CD3, with or without ATP supplementation (100 µm) in the culturemedium, and analyzed for surface CD25 activationmarker expression (H and I) and IFN-γ effector
cytokine production (J) at day 3. n = 3–6. (K)Western blot analysis of TCR signaling events in CrT-WT and CrT-KO CD8 T cells. CrT-WT and CrT-KO CD8 T cells were
stimulated with anti-CD3 for 48 h, rested at 4°C for 2 h, then restimulated with anti-CD3 for 30 min followed by Western blot analysis. (L)Western blot analysis of
TCR signaling events in CrT-KO CD8 T cells with or without ATP supplementation. CrT-KO CD8 T cells were stimulated with anti-CD3 for 48 h, rested at 4°C for 2 h,
then restimulated with anti-CD3 for 30 min in the presence or absence of ATP supplementation (100 µm) followed by Western blot analysis. (M) Western blot
analysis of TCR signaling events in CrT-WT and CrT-KO CD8 T cells with or without AICAR treatment. CrT-WT and CrT-KO CD8 T cells were pretreated with AICAR
(2 mM) for 30 min, then stimulated with anti-CD3 for 20 min followed by Western blot analysis. DMSO, solvent used to dissolve AICAR. (N) Schematic model
showing creatine uptake regulation of T cell activation signaling events. The demonstrated pathways are highlighted in red and blue. Representative of two ex-
periments (B–M). Data are presented as the mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 by Student’s t test. See also Fig. S4.
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Taken together, these results demonstrate the capacity of
creatine supplementation to boost antitumor T cell immunity,
thus suggesting its potential as a new means of cancer
immunotherapy.
Creatine supplementation for combination cancer therapy
Many successful and in-development cancer immunotherapies
target metabolic reprogramming of immune response in the
tumor microenvironment (McCarthy et al., 2013; Ho and Kaech,
2017; Kishton et al., 2017; Patel and Powell, 2017). In particular,
checkpoint blockade therapies, such as PD-1/PD-L1 blockade
therapies, have been indicated to correct the glucose usage im-
balance between tumor cells and T cells by altering glycolysis
and directing the energy metabolism to favor T cells (Gubin
et al., 2014; Chang et al., 2015; Baumeister et al., 2016; Bengsch
et al., 2016; Scharping et al., 2016). By providing a potent and
nonredundant energy buffering benefit for tumor-fighting
T cells, we postulate that creatine supplementation may syner-
gize with a PD-1/PD-L1 blockade therapy to further improve
cancer treatment efficacy. Indeed, in a mouse MC38 colon cancer
model sensitive to PD-1/PD-L1 blockade therapy (Homet Moreno
et al., 2016), the combination of creatine supplementation and
anti–PD-1 treatment generated a significant tumor suppression
effect superior to that of each treatment alone (Fig. 6, A and B). In
fact, most (four of five) experimental mice receiving the combi-
nation therapy completely eradicated their tumor burden and
remained tumor-free for >3 mo (Fig. 6 C). When receiving a
second challenge of MC38 tumor cells, all these “cancer survi-
vors” were protected from tumor recurrence and stayed tumor-
free for another 6 mo, the duration of the experiment (Fig. 6 C).
This appealing tumor protection effect was associated with a
significant increase of memory-phenotype CD8 T cells in the
surviving mice, most likely generated from the successful anti-
tumor T cell response in the initial tumor challenge and later on
used by the surviving mice to fight off a second tumor challenge
(Fig. 6, D and E). Collectively, these encouraging results suggest a
promising potential of creatine supplementation for combination
cancer immunotherapy.
Discussion
Based on our findings, we propose a “hybrid engine” model to
update the molecular machinery that powers antitumor T cell
immunity by incorporating creatine into the picture (Fig. 7).
Figure 5. Creatine supplementation for cancer immunotherapy. (A–G) Studying the therapeutic potential of creatine supplementation in a B16-OVA
melanoma model. (A) Experimental design. (B) Creatine levels in serum (n = 5). (C) Tumor progression (n = 8–10). (D–G) On day 17, tumors and muscles were
collected from experimental mice for further analysis. (D) FACS plots showing the phenotype of tumor-infiltrating CD8 T cells. (E)Quantification of D (n = 4–6).
(F) H&E-stained skeletal muscle sections. Scale bar: 100 µm. (G)Quantification of F (n = 3). (H and I) Studying the requirement of an intact immune system for
cancer therapy effects. (H) Experimental design. (I) Tumor progression (n = 5). NSG, NOD/SCID/γc−/− immunodeficient mice. (J and K) Studying the re-
quirement of T cells for creatine cancer therapy effects. I.p. injection of an anti-CD3 depleting antibody (αCD3, clone 17A2) was used for in vivo depletion of
T cells. (J) Experimental design. (K) Tumor progression (n = 5–9). Representative of two (H–K) and three (A–G) experiments. Data are presented as the mean ±
SEM. ns, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 by one-way ANOVA (B, C, E, G, and K) or Student’s t test (I). See also Fig. S5.
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Analogous to the popular hybrid car, which uses two distinct
sources of power, a tumor-targeting CD8 T cell utilizes a “mo-
lecular fuel engine” such as glycolysis and/or tricarboxylic acid
cycle to convert nutrients/biofuels (e.g., glucose, amino acids,
and lipids) into bioenergy in the form of ATP, while using
creatine as a “molecular battery” to store bioenergy and buffer
the intracellular ATP level, to support T cell antitumor activities
(Fig. 7 B). This hybrid engine system is energy efficient, enabling
a tumor-targeting CD8 T cell to make maximal use of its avail-
able bioenergy supply and perform in a metabolically stressful
Figure 6. Creatine supplementation for
combination cancer therapy. Studying the
therapeutic potential of creatine supplementa-
tion in combination with anti–PD-1 (αPD-1)
treatment in an MC38 colon cancer model.
(A) Experimental design. (B) Tumor progression
at phase-1 (n = 4–5). (C) Tumor progression at
phase-2 (n = 3–4). (D) Detection of memory CD8
T cells (gated as CD8+CD44hi) in blood of tumor-
bearing mice at phase-2. (E) Quantification of D
(n = 3–4). Representative of two experiments
(A–E). Data are presented as the mean ± SEM. *,
P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P <
0.0001 by one-way ANOVA (B) or Student’s
t test (E). See also Fig. S5.
Figure 7. The hybrid engine model: an up-
dated view of the molecular machinery that
powers antitumor T cell immunity. (A) Nu-
trients that serve as the biofuels, which can be
limiting in the tumor microenvironment. (B) The
hybrid enginemodel. To analogize the hybrid car,
a tumor-targeting CD8 T cell utilizes a “molec-
ular fuel engine,” such as aerobic glycolysis and/
or tricarboxylic acid cycle, to convert nutrients/
biofuels into bioenergy in the form of ATP, while
using creatine as a “molecular battery” to store
bioenergy and buffer the intracellular ATP level
to power T cell antitumor activities. (C) Creatine
can be obtained from creatine-rich dietary re-
sources, mainly red meat, poultry, and fish, as
well as from dietary supplements. (D) However,
the best cancer therapy benefits would come
from clinical intervention by administering cre-
atine to cancer patients following specially de-
signed dosing strategies.
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microenvironment where it has to compete with fast-growing
tumor cells for a limited supply of nutrients (Fig. 7 A; Fox et al.,
2005; Siska and Rathmell, 2015;Wherry and Kurachi, 2015). CD8
T cells have limited capacity to de novo synthesize creatine;
therefore, they heavily rely on uptake of creatine from extra-
cellular resources via CrT (Fig. 7 B), all of which opens up the
possibility of reinvigorating tumor-fighting CD8 T cells through
creatine supplementation. Creatine can be obtained from
creatine-rich dietary resources, mainly red meat, poultry, and
fish, as well as from dietary supplements (Wyss and Kaddurah-
Daouk, 2000; Kreider et al., 2017; Fig. 7 C). However, the best
cancer therapy benefits would come from clinical intervention
by administering creatine to cancer patients following specially
designed dosing strategies (Fig. 7 D). Both oral and direct ad-
ministration (e.g., intravenous) routes can be effective (Fig. 7 D).
Our study showed that creatine supplementation suppressed
tumor growth in multiple mouse tumor models, including the
B16 melanoma model (Fig. 5) and the MC38 colon cancer model
(Fig. 6), suggesting that this treatment may provide a general
therapeutic benefit to many different types of cancer. Moreover,
because creatine works through a novel “energy-buffering”
mechanism that is nonredundant to the mechanisms used by
many successful and in-development immunotherapies, crea-
tine supplementation can potentially become an effective and
economical common component for combination cancer im-
munotherapies. In our study, we showed that creatine supple-
mentation synergized with checkpoint blockade therapies such
as the PD-1/PD-L1 blockade therapy to yield superior therapeutic
efficacy (Fig. 6). Many other cancer therapeutic modalities, in-
cluding the booming new immunotherapies as well as tradi-
tional chemotherapies and radiation therapies, may also benefit
from combining with creatine supplementation treatment
(Fig. 7 D; Pardoll, 2012; Couzin-Frankel, 2013; Page et al., 2014;
Ribas, 2015; Rosenberg and Restifo, 2015; Baumeister et al., 2016;
Lim and June, 2017).
In the past three decades, oral creatine supplements have
been broadly used by bodybuilders and athletes to gain muscle
mass and improve performance (Wyss and Kaddurah-Daouk,
2000; Kreider et al., 2017). The new discovery that creatine
supplementation may help build a stronger immune system in
addition to building a stronger body is exciting. For the active
users of creatine supplements, this discovery means possible
additional health benefits; for disease patients, it means new
immunotherapeutic opportunities. The well-documented safety
of long-term creatine supplementation in humans affords a
green light for using creatine supplementation to treat chronic
diseases such as cancer (Kreider et al., 2017). Meanwhile, the
muscle enhancement effect of creatine supplementation, as
demonstrated from human experience and shown in our animal
studies (Fig. 5, F and G), may also benefit cancer patients who at
their late stages often suffer from cachexia, or wasting syn-
drome (de Campos-Ferraz et al., 2014). Interestingly, some early
studies showed that creatine and creatine analogues could di-
rectly inhibit cancer growth, presumably through disrupting
cancer cell metabolism, suggesting an additional mechanism
that creatine may employ to mediate its antitumor effects
(Miller et al., 1993; Kristensen et al., 1999). Conversely, CrT has
been suggested as a possible biomarker for circulating tumor
cells within the blood, posing the concern that creatine supple-
ment may have potential negative effects on CrT-positive tu-
mors (Riesberg et al., 2016). Interestingly, for the two mouse
tumormodels used in our study, B16melanoma cells express CrT
(as well as creatine kinase brain form) while MC38 colon cancer
cells do not (Fig. S5 B). Creatine supplementation exhibited tu-
mor suppression benefits in both tumor models (Fig. 5 C and
Fig. 6 B), suggesting that this therapy may have the potential to
treat both CrT-positive and CrT-negative tumors.
The energy-buffering function of creatine certainly goes
beyond regulating CD8 T cells. In CrT-KO mice, we have ob-
served the hyporesponsiveness of multiple immune cells in
various mouse tumor models. It is also likely that creatine reg-
ulates immune reactions to multiple diseases beyond cancer,
such as infections and autoimmune diseases (Riesberg et al.,
2016). Studying the roles of creatine in modulating various im-
mune cells under different health and disease conditions will be
interesting topics for future research.
Materials and methods
Mice
C57BL/6J (B6) and B6.SJL-PtprcaPepcb/BoyJ (CD45.1, BoyJ) mice
were purchased from the Jackson Laboratory, and 6–10-wk-old
mice were used for all experiments, unless otherwise indicated.
B6(Cg)-Slc6a8tm1.2Clar/Jmice, referred to as CrT-KOmice, were
purchased from the Jackson Laboratory (Skelton et al., 2011).
The experimental colony was produced by breeding female
hemizygous mice with male WT littermates. 6–10-wk-old mice
were used for all experiments, unless otherwise indicated.
C57BL/6-Tg(TcraTcrb)1100Mjb/J (OT1 Tg) mice were purchased
from the Jackson Laboratory and bred with the CrT-KO mice to
generate OT1TgCrT-WT and OT1TgCrT-KO mice. 6–10-wk-old mice
were used for all the experiments, unless otherwise indicated.
NOD.Cg-PrkdcSCIDIl2rgtm1Wjl/SzJ (NOD/SCID/IL-2Rγ−/−, NSG) mice
were purchased from the Jackson Laboratory. 6–10-wk-old fe-
males were used for all experiments, unless otherwise indicated.
The animals were housed under specific pathogen–free
conditions with 12-h day/night cycles. All animal experiments
were approved by the Institutional Animal Care and Use Com-
mittee of the University of California, Los Angeles (UCLA).
Antibodies and flow cytometry
Fluorochrome-conjugated monoclonal antibodies specific for
mouse CD45.2 (109820; clone 104), TCRβ (109220; clone H57-
597), CD4 (100531; clone RM4-5), IFN-γ (505806; clone XMG1.2),
Granzyme B (372208; clone QA16A02), TCR Vα2 (127809; clone
B20.1), CD69 (104508; clone H1.2F3), CD25 (102006; clone PC61),
CD8 (100732; clone 53-6.7), CD44 (103030; clone IM7), LAG-3
(CD223; 125207; clone C9B7W), and Tim-3 (CD366; 119705; clone
RMT3-23) were purchased from BioLegend. Monoclonal anti-
bodies specific for mouse IL-2 (554428; clone JES6-5H4); TCR
Vβ5 (1553190; clone MR9-4); and Fc block (anti-mouse CD16/32;
553142; clone 2.4G2) were purchased from BD Biosciences.
Monoclonal antibody specific for mouse PD-1 (12-9981-83; clone
RMPI-30) was purchased from the eBioscience. Fixable Viability
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Dye eFluor 506 (65-0866) was purchased from Thermo Fisher
Scientific. Cells were stained with Fixable Viability and Fc
blocking dye first, followed by surface marker staining. To de-
tect intracellular molecules (Granzyme B and cytokines), cells
were subjected to intracellular staining using a Cell Fixation/
Permeabilization Kit (554714; BD Biosciences), following the
manufacturer’s instructions. To analyze cell viability, cells were
stained with Annexin V and 7-AAD using a FITC Annexin V
Apoptosis Detection Kit (640922; BioLegend), following the
manufacturer’s instructions. Stained cells were analyzed using a
MACSQuant Analyzer 10 Flow Cytometer (Miltenyi Biotec).
FlowJo software (TreeStar) was used to analyze the data.
Purified anti-mouse CD3 antibody (100314; clone 145-2C11)
used for in vitro stimulation of CD8 T cells was purchased from
BD Biosciences. Anti-mouse CD3 depleting antibody (BE0002;
clone 17A2) and its isotype control antibody (BE0090; clone LTF-
2), as well as anti-mouse PD-1 blocking antibody (BE0146; clone
RMP1-14) and its isotype control antibody (BE0089; clone 2A3),
used for in vivo animal study were purchased from BioXCell.
Mouse tumor models
B16-OVA murine melanoma cells (obtained from the laboratory
of PinWang, University of Southern California, Los Angeles, CA;
Liu et al., 2014) and MC38 murine colon adenocarcinoma cells
(obtained from the laboratory of Antoni Ribas, UCLA, Los An-
geles, CA; Homet Moreno et al., 2016) were cultured in high-
glucose (4.5 g/liter) DMEM supplemented with 10% FBS and
penicillin-streptomycin (Thermo Fisher Scientific) at 37°C and
with 5% CO2.
To establish solid tumors, mice were s.c. injected above the
right flank with 106 B16-OVA or 3 × 105 MC38 cells. Before in-
jection, cells in log phase of growth were harvested and sus-
pended in PBS, and 50 µl of cell suspension were s.c. injected
above the flank. Tumor size was periodically measured with a
digital Vernier caliper (Thermo Fisher Scientific).
BM transfer
BM cells were prepared from femurs and tibias by flushing with
25G needles. BM cells from CrT-KO mice were administered by
retroorbital injection to BoyJ female recipient mice that had
received 1,200-rad total-body irradiation. Control BoyJ recipient
mice received BM cells from the CrT-WT littermates. In both
groups, 8 × 106 CrT-WT or CrT-KO BM cells were injected into
recipient mice. BM recipient mice were housed in a sterile
environment and maintained on the combined antibiotics
sulfmethoxazole and trimethoprim oral suspension (Septra;
Hi-Tech Pharmacal) for 12 wk until analysis or use for further
experiments. Blood was collected by retroorbital bleeding and
analyzed by flow cytometry to confirm the reconstitution. Tu-
mor inoculation started 12 wk after BM transfer.
Isolation of OT1 Tg T cells and adoptive T cell transfer
The OT1 Tg T cells were purified from the spleen and lymph
node cells of either OT1TgCrT-WT or OT1TgCrT-KO mice (denoted
as OT1CrT-WT or OT1CrT-KO cells, respectively) through magnetic-
activated cell sorting (MACS) using a mouse CD8 T Cell Isolation
Kit (120117044; Miltenyi Biotec) according to the manufacturer’s
instructions. The purified OT1CrT-WT or OT1CrT-KO cells were then
used for in vitro culture or in vivo adoptive T cell transfer
studies.
For adoptive T cell transfer, BoyJ female mice (referred to as
recipient mice) were injected s.c. above the right flank with 106
B16-OVA cells. 7 d after tumor inoculation, recipient mice re-
ceived 600-rad total-body irradiation, followed by retroorbital
injection of purified OVA-specific OT1 Tg T cells (105 OT1 T cells
per mouse).
TII cell isolation and analysis
Solid tumors were collected from experimental mice at the
termination of each tumor experiment. Tumors were cut into
small pieces and smashed against a 70-µm cell strainer (07-201-
431; Corning) to prepare single cells. Immune cells were en-
riched through gradient centrifugation with 50% Percoll (P4937;
Sigma-Aldrich) at 800 g for 30 min at room temperature
without brake, followed by treatment with Tris-buffered am-
monium chloride buffer to lyse red blood cells according to a
standard protocol (Cold Spring Harbor Protocols). The resulting
TIIs were then used for further analysis.
To assess gene expression, CD45+ immune cells were sorted
from TIIs using flow cytometry and then analyzed for CrTmRNA
expression using qPCR. To assess T cell activation status, TIIs
were analyzed for surface activation marker (CD25 and PD-1)
expression using flow cytometry. To assess T cell cytotoxicity,
TIIs were analyzed for intracellular Granzyme B expression
using flow cytometry. To assess T cell cytokine production, TIIs
were stimulated with PMA (50 ng/ml) + ionomycin (500 ng/ml)
in the presence of GolgiStop (4 µl per 6-ml culture) for 4 h, then
analyzed for intracellular cytokine (IL-2 and IFN-γ) produc-
tion using flow cytometry. CD8 T cells were identified by
costaining TIIs with cell surface lineage markers (gated as
CD45+TCRβ+CD4−CD8+ cells).
CD8 T cell isolation, in vitro culture, and analysis
Spleen and lymph node cells were harvested from experimental
mice and were subjected to MACS using a mouse CD8 T Cell
Isolation Kit (Miltenyi Biotec) according to the manufacturer’s
instructions. The resulting purified CD8 T cells were then used
for in vitro culture and analysis.
CD8 T cells were cultured in vitro in standard T cell culture
medium comprising RPMI 1640 (10040; Corning), 10% FBS
(F2442; Sigma-Aldrich), 1% penicillin-streptomycin-glutamine
(10378016; Gibco), 1% MEM Non-Essential Amino Acids Solu-
tion (11140050; Gibco), 1% Hepes (15630080; Gibco), 1% sodium
pyruvate (100 mM; 11360070; Gibco), and 0.05 mM
β-mercaptoethanol (M3148; Sigma-Aldrich). Unless otherwise
indicated, cells were seeded at 0.5 × 106 cells per well in 24-well
plates and stimulated with plate-bound anti-CD3 (5 µg/ml; clone
145-2C11), for ≤5 d. At indicated time points, cells were collected
and analyzed for CrT mRNA expression using qPCR, for cell
proliferation through cell counting, for viability through An-
nexin V/7-AAD staining followed by flow cytometry analysis, for
surface activation marker (CD25) expression through surface
staining followed by flow cytometry analysis, for effector mol-
ecule (Granzyme B, IL-2, and IFN-γ) production through
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intracellular staining followed by flow cytometry analysis, and
for cytokine (IL-2 and IFN-γ) secretion through collecting cell
culture supernatants followed by ELISA analysis. CrT protein
expression and TCR signaling events were analyzed using
Western blot analysis.
In some experiments, ATP (A6419; Sigma-Aldrich) was re-
constituted in sterile PBS and added to T cell culture (100 µM)
for 2–3 d along with anti-CD3 stimulation, followed by analyzing
T cell surface activation marker (CD25) expression using flow
cytometry and effector cytokine (IFN-γ) secretion using ELISA.
In some experiments, T cells were stimulated with anti-CD3 for
48 h, rested at 4°C for 2 h, then restimulated with anti-CD3 for
30 min in the presence or absence of ATP supplementation
(100 µM) followed by analyzing TCR signaling events using
Western blot.
In some other experiments, AICAR (A9978; Sigma-Aldrich),
an AMPK activator, was reconstituted in DMSO and used to
pretreat T cells for 30 min at a concentration of 2 mM, followed
by 20 min of anti-CD3 stimulation for Western blot analysis of
TCR signaling events, or at a concentration of 250 µM followed
by 16 h of anti-CD3 stimulation for flow cytometry analysis of
CD25 expression and ELISA analysis of IL-2 production.
For in vitro creatine supplementation experiments, creatine
monohydrate (C3630; Sigma-Aldrich) was reconstituted in
standard T cell culture medium and added to T cell culture.
T cells were stimulated with anti-CD3 for 48 h in the presence or
absence of creatine supplementation (0.5 mM), rested at 4°C for
2 h, then restimulated with anti-CD3 for 10 min in the presence
or absence of creatine supplementation (0.5 mM) followed by
TCR signaling events analysis using Western blot.
MIG mock and MIG-CrT retroviruses
MIG mock retroviral vector was reported previously (Smith
et al., 2015; Li et al., 2017). MIG vector is derived from the mu-
rine stem cell virus and contains an internal ribosome entry site
linked to an enhanced GFP reporter gene. The MIG-CrT con-
struct was generated by inserting the mouse CrT (Slc6A8) cDNA
(codon-optimized; synthesized by IDT) into the MIG retroviral
vector. The CrT cloning sequences are as follows: forward, 59-
GTCTCTCCCCCTTGAACCTCCTCGTTC-39, and reverse, 59-CAA
GCGGCTTCGGCCAGTAACG-39. Retroviruses were produced
using HEK293T cells following a standard calcium precipitation
method (Smith et al., 2015; Li et al., 2017). For viral transduction,
CD8 T cells isolated from the spleen and lymph nodes of CrT-KO
micewere stimulated in vitrowith plate-bound anti-CD3 (5 µg/ml)
for 4 d. On days 2 and 3 following stimulation, cells were spin
infected with retroviral-containing supernatants supple-
mented with 10 µg/ml polybrene (TR-1003-G; Millipore) for
90 min at 770 g at 30°C. On day 4, cells were collected for
analysis.
mRNA qPCR analysis
Total RNA was isolated using TRIzol reagent (15596018; In-
vitrogen, Thermo Fisher Scientific) according to the manu-
facturer’s instructions. cDNA was prepared using a SuperScript
III First-Strand Synthesis Supermix Kit (18080400; Invitrogen,
Thermo Fisher Scientific). Gene expression was measured using
a KAPA SYBR FAST qPCR Kit (KM4117; Kapa Biosystems) and a
7500 Real-time PCR System (Applied Biosystems) according to
the manufacturers’ instructions. Ube2d2 (for T cells) or Actb (for
tumor cells) was used as an internal control. qPCR was per-
formed using the following primers: CrT forward, 59-ACTGGG
AGGTGACCTTGTGC-39, and reverse, 59-CGATCTTTCCTGTTG
ACTTG-39; Ckb forward, 59-AGTTCCCTGATCTGAGCAGC-39, and
reverse, 59-GAATGGCGTCGTCCAAAGTAA-39, Agat forward, 59-
GCTTCCTCCCGAAATTCCTGT-39, and reverse, 59-CCTCTAAAG
GGTCCCATTCGT-39; Gamt forward, 59-CACGCACCTGCAAAT
CCTG-39, and reverse, 59-CACGCACCTGCAAATCCTG-39; Ube2d2
forward, 59-ACAAGGAATTGAATGACCTGGC-39, and reverse, 59-
CACCCTGATAGGGGCTGTC-39; and Actb forward, 59-AGGTGT
GCACCTTTTATTGGT-39, and reverse, 59-TGTATGAAGGTTTGG
TCTCCC-39. The relative expression of the mRNA of interest was
calculated using the 2ΔΔCT method.
ELISA
ELISA was performed for the detection of cytokines according to
a BD Biosciences protocol. The coating and biotinylated anti-
bodies for the detection of mouse IFN-γ (coating antibody,
554424; biotinylated detection antibody, 554426) and IL-
2 (coating antibody, 551216; biotinylated detection antibody,
554410) were purchased from BD Biosciences. The streptavidin-
HRP conjugate (18410051) was purchased from Invitrogen.
Mouse IFN-γ and IL-2 standards were purchased from eBio-
science. The 3,39,5,59-tetramethylbenzidine (51200048) sub-
strate was purchased from KPL. The absorbance was measured
at 450 nm using an Infinite M1000 microplate reader (Tecan).
Western blot
Total protein was extracted using radioimmunoprecipitation
assay lysis buffer (Thermo Fisher Scientific) supplemented with
a phosphatase inhibitor cocktail (Sigma-Aldrich) and a protease
inhibitor cocktail (Roche) following the manufacturers’ in-
structions. Nuclear protein was extracted using a Nuclear Pro-
tein Extraction Kit (Thermo Fisher Scientific) following the
manufacturer’s instructions, or using homemade reagents
(10 mMHepes, pH 7.9, 10mMKCl, 0.34M sucrose, 10% glycerol,
1 mM dithiothreitol, 0.1% Triton X-100, 1.5 mM MgCl2, and
protease inhibitor cocktail) following a previously established
protocol (Ma et al., 2019). Protein concentration was measured
by a BCA assay (23228 and 1859078; Thermo Fisher Scientific).
Equal amounts of protein were resolved on a 12% SDS-PAGE gel
and then transferred to a polyvinylidene difluoride membrane
by electrophoresis. The following anti-mouse antibodies were
purchased from Cell Signaling Technology and used to blot for
the protein of interest: p-Zap-70 (2705S; clone 99F2); Zap-70
(2717S; clone Y319); p-Lck (2751S; clone Y505); Lck (2752S);
p-c-Jun (9261S; clone S63); NFAT (4389S); NF-κB p65 (8242P;
clone D14E12); AMPK (5831T; clone D5A2); p-AMPK (2535T;
clone 40H9), secondary anti-mouse (7076P2), and secondary
anti-rabbit (7074P2). Anti-mouse CrT (SLC6A8; PA5-37060) was
purchased from Thermo Fisher Scientific. β-Actin (sc-69879;
clone AC-15; Santa Cruz Biotechnology) was used as an internal
control for total protein extracts, while Lamin A (sc-71481; clone
4A58; Santa Cruz Biotechnology) was used as an internal control
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for nuclear protein extracts. Signals were visualized with au-
toradiography using an enhanced chemiluminescence system
(RPN2232; Thermo Fisher Scientific). Data analysis was per-
formed using ImageJ software (National Institutes of Health).
ATP quantification
A Luminescent ATP Detection Assay Kit (ab113849; Abcam) was
used to quantify intracellular ATP, following the manufacturer’s
instructions. The total amount of ATP detected was then nor-
malized to cell numbers.
Creatine quantification
A Creatine Assay Kit (ab65339; Abcam) was used to quantify
creatine, both in vivo and in vitro, following the manufacturer’s
instructions. For the in vivo study, whole blood was collected
(retroorbital bleeding) from the experimental mice in a capillary
tube, and the isolated serum was immediately used for the assay
following the manufacturer’s directions. For the in vitro study,
cells were spun to remove culture media and suspended in cold
PBS. Creatine was then quantified following the manufacturer’s
directions. The total amount of creatine detected was then
normalized to cell numbers.
In vivo study of creatine supplementation for
cancer immunotherapy
For creatine supplementation via i.p. injection, creatine mono-
hydrate (C3630; Sigma-Aldrich) was dissolved in sterile PBS and
injected i.p. in experimental animals daily at a dose of 10.5 mg
per animal per injection. For creatine supplementation via diet,
experimental animals were fed a creatine-enriched isocaloric
diet, which is a customized formulation based on PicoLab Rodent
Diet 20 enriched in creatine (3 g/kg diet, TD.170082; Envigo
Teklad Diet). The diet was designed to reflect the safe daily dose
of creatine recommended for enhanced athletic performance in
humans (Mayo Clinic data). Nontreated mice (control) were fed
a control diet prepared in a manner similar to that of the
creatine-enriched diet.
To study the effects of creatine supplementation on sup-
pressing tumor growth, B6 mice were inoculated with B16-
OVA tumor cells and monitored for tumor growth, with or
without receiving creatine supplementation via i.p. injection
or diet. To study the requirement of an immune system for
creatine supplementation–induced antitumor effects, B16-
OVA tumor growth was compared between B6 mice and
immune-compromised NSG mice receiving i.p. supplemen-
tation of creatine. To study the T cell dependence of creatine
supplementation–induced antitumor effects, B6-OVA tumor
growth was monitored and compared in B6 mice receiving i.p.
injection of an anti-CD3 T cell–depleting antibody (clone
RMP1-14; 100 µg/mouse/injection, twice per wk) or an isotype
control antibody (clone LTF-2, 100 µg/mouse/injection, twice
per wk), with or without i.p. supplementation of creatine.
To study the combination effects of creatine supplementation
and PD-1/PD-L1 blockade treatment, B6 mice were inoculated
with MC38 tumor cells and monitored for tumor growth; ex-
perimental mice also received i.p. supplementation of creatine,
as well as i.p. injection of an anti–PD-1 blocking antibody (clone
RMP1-14; 300 µg/mouse/injection, twice per wk) or an isotype
control antibody (clone 2A3; 300 µg/mouse/injection, twice per
wk), alone or in combination. Tumor-free mice weremaintained
for 3 mo, then challenged with MC38 tumor cells again and
monitored for tumor recurrence over another 6-mo period.
Histological analysis
Skeletal muscle (biceps femoris) harvested from control and
experimental (creatine i.p. and food) mice were fixed in 10%
neutral-buffered formalin and embedded in paraffin for sec-
tioning (5-µm thickness), followed by H&E staining using
standard procedures (UCLA Translational Pathology Core Lab-
oratory). The sections were imaged using an Olympus BX51
upright microscope equipped with a Macrofire charge-coupled
device camera (Optronics). The muscle-fiber diameter was as-
sessed with the use of ImageJ.
Quantification and statistical analysis
FlowJo software (TreeStar) was used for the analysis of FACS
data. ImageJ was used to quantify Western blots and muscle
H&E sections. GraphPad Prism 6 was used for graphic repre-
sentation and statistical analysis of the data. Pairwise compar-
isons were made using a two-tailed Student’s t test. Multiple
comparisons were performed using an ordinary one-way
ANOVA, followed by Tukey’s multiple comparisons test. Data
are presented as the mean ± SEM, unless otherwise indicated. A
P value <0.05 was considered significant. *, P < 0.05; **, P < 0.01;
***, P < 0.001; ****, P < 0.0001.
Online supplemental material
Fig. S1 shows the characterization of CrT-KO mice, the study of
tumor growth in CrT-WT and CrT-KO mice without creatine
supplementation, and the CrT mRNA expression in tumor-
infiltrating CD8 T cell subsets. Fig. S2 shows the BM transfer
experiment studying whether CrT deficiency in the immune
system directly impacts tumor growth. The figure also shows
additional data studying the in vivo antitumor capacity of CrT-
WT and CrT-KO OT1 Tg T cells. Fig. S3 shows the creatine level
in standard T cell culture medium and the in vitro activation of
CrT-WT and CrT-KO antigen-specific CD8 T cells. The figure also
shows additional data studying CrT-KO CD8 T cells transduced
with MIG-CrT retrovector. Fig. S4 shows the study of CrT-WT
CD8 T cell activation with ATP supplementation, the study of
CrT-WT and CrT-KO CD8 T cell activation with or without
AICAR treatment, and the study of CrT-WT and CrT-KO CD8
T cell proximal signaling activation with or without creatine
treatment. Fig. S5 shows the in vivo depletion of T cells in B6
mice using an anti-CD3 depleting antibody, and the study of CrT
and Ckb mRNA expression in B16-OVA and MC38 tumor cells.
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